A5026751777- Inflammatory Bowel Disease
- Microscopic Colitis
- Celiac Disease Research and Management
- Adolescent and Pediatric Healthcare
- Autoimmune Bullous Skin Diseases
- Immunodeficiency and Autoimmune Disorders
- Pediatric Hepatobiliary Diseases and Treatments
- COVID-19 Clinical Research Studies
- Dermatological and COVID-19 studies
- Urticaria and Related Conditions
- Pharmaceutical studies and practices
- Intestinal Malrotation and Obstruction Disorders
- Liver Diseases and Immunity
- Gastrointestinal disorders and treatments
- Long-Term Effects of COVID-19
- Digestive system and related health
- Autoimmune and Inflammatory Disorders Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
Istituto Giannina Gaslini
2023-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2024-2025
Royal Hospital for Sick Children
2024-2025
Royal Hospital for Children
2024-2025
University of Genoa
2022-2023
Abstract Background Long-term data on the efficacy and safety of biologics in pediatric inflammatory bowel disease (IBD) are crucial for guiding clinicians optimizing their use. This study aims to evaluate real-life durability, usage patterns, factors influencing treatment discontinuation IBD. Methods registry-based analyzed patients from IBD registry Italian Society Pediatric Gastroenterology, Hepatology Nutrition (SIGENP) who started biologic therapy between 2009 2022, with a minimum...
Abstract Background Oral vancomycin has had limited use in paediatric Inflammatory Bowel Disease (PIBD), with reported efficacy primary sclerosing cholangitis (PSC-PIBD)1, acute severe colitis as part of a quadruple antibiotic regimen2, and very early onset IBD3. This study evaluates its effectiveness safety single-agent therapy non-PSC PIBD patients. Methods single-centre retrospective cohort included patients started on oral for active IBD or steroid/topical dependency from 01/2017 to...
Abstract Background Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of as an induction pediatric UC IBD-U. Methods In this multicenter retrospective study, treated for remission active IBD-U from 30 centers worldwide were enrolled. Demographic, clinical laboratory data well adverse events (AEs) recorded at week 8 post induction. Results One hundred included...
Abstract Background and Aims Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness safety of as an induction pediatric UC IBD-U. Methods In this multicenter retrospective study, treated for remission active IBD-U from 30 centers worldwide were enrolled. Demographic, clinical laboratory data well adverse events (AEs) recorded at week 8 post induction. Results One hundred...
Celiac disease (CD) is an immune-mediated systemic gluten-related disorder characterized by a wide spectrum of intestinal and extra-intestinal manifestations, including damage to cutaneous connective tissue. We report rare case chronic severe dermatitis involving tissue vascular vessels as the main clinical presentation undiagnosed seronegative gluten disorder. A gluten-free diet dramatically improved in patient. Pitfalls steps differential diagnosis are described. also review literature...
Abstract Background Genetic syndromes are associated with a strong susceptibility to autoimmune disorders an increased risk of developing inflammatory bowel diseases (IBD). However, data regarding the impact genetics in development IBD limited (Gatti S. et al, Frontiers Pediatrics 2021). Furthermore, patients genetic affected by multiple comorbidities which increase diagnostic and therapeutic complexity as well adverse reactions drugs. Methods In this retrospective, multicenter case-control...
Treatment of infantile-onset inflammatory bowel disease (IO-IBD) is often challenging due to its aggressive course and failure standard therapies with a need for biologics. Secondary loss response frequently caused by the production anti-drug antibodies, well-known problem in IBD patients on biologic treatment. We present case IO-IBD treated therapeutic drug monitoring (TDM)-guided high-dose anti-tumor necrosis factor therapy, which dose escalation was used as strategy overcome antibodies.A...
Abstract Introduction Most coronavirus disease 2019 (COVID-19) pediatric patients are asymptomatic; however, several neurological manifestations associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection have been reported. Demyelinating events such as disseminated encephalomyelitis recently included among potential complications of COVID-19. Case Report We describe the case a 12-year-old boy who developed central nervous system demyelinating lesions following...